The Singapore Translational Cancer Consortium (STCC) was established in 2020 as a nationally coordinated initiative and network to synergize cancer research and translational capabilities across Singapore.
The STCC joint platform enables collaboration between basic, clinical and translational researchers to explore novel approaches, push promising lines of research and translation, and seed ideas for larger competitive translational grants.
SINGAPORE – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd).
Singapore Translational Cancer Consortium, National Cancer Centre Singapore, National University Hospital and Roche signed a Memorandum of Understanding (MOU) to leverage data insights and deepen understanding of unique drivers of disease to help improve health outcomes
Biomedical research is overseen by numerous Institutional Review Boards (IRBs) in Singapore but there has been no research that examines how the research review process is perceived by the local research community nor is there any systematic data on perceptions regarding the review process or other research ethics processes and IRB characteristics.
This expert opinion review examines the key challenges to the clinical adoption of NGS-based diagnostics in Singapore, provides recommendations on impactful initiatives to improve adoption, and also offers practical guidance on specific cancer types in which NGS-based diagnostics are appropriate for use in Singapore.
We partner with key stakeholders and institutions to implement joint platforms that are functionally integrated and operational in support of the nation’s long term goals to achieve value-based healthcare and economic outcomes through deeper industry collaborations, patents and invention disclosures, start-ups and clinically validated diagnostics.